Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FZ837
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,838
Award facts
- Contract value 100% obligated
- $14,837.67 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $14,837.67 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, represents one of numerous orders placed under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The PPV-G GEN V is part of a broader $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors capable of supplying comprehensive pharmaceutical products, including branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support Department of Defense healthcare operations globally. No set-aside designation was used for this delivery order, demonstrating the contractor's competitive capability in unrestricted federal procurement.
DMS Pharmaceutical Group, registered in the System for Award Management since 2001, has established itself as a critical supplier within the federal pharmaceutical supply chain through consistent performance across multiple therapeutic categories and product lines. The company's product portfolio encompasses oncology treatments, immunosuppressants, emergency medications, specialty surgical products, vaccines, and routine pharmaceuticals. Under its PPV-G GEN V prime vendor contract awarded in November 2025 with a $499,999,999 ceiling and completion date of December 31, 2036, DMS Pharmaceutical Group is authorized to receive firm fixed-price delivery orders from the DLA to fulfill the diverse and specialized pharmaceutical requirements of military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DU26FZ837?
SPE2DU26FZ837 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DU26FZ837 worth?
The government has obligated $14,838 on SPE2DU26FZ837.
Is contract SPE2DU26FZ837 an order under another contract?
Yes. SPE2DU26FZ837 is a delivery order under SPE2DU25D9434, an indefinite delivery contract.
Was contract SPE2DU26FZ837 competed?
The extent of competition for SPE2DU26FZ837 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award